Showing results (361-370 of 673) with videos related to

Sort By:
Pageof 68
HIV Clinical Trials|March 11, 2011
Belief in AIDS origin conspiracy theory and willingness to participate in biomedical research studies: findings in whites, blacks, and Hispanics in seven cities across two surveysStefanie L Russell, Ralph V Katz, Min Qi Wang, et al.
HIV Clinical Trials|December 4, 2010
Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164Paul E Sax, Caroline E Sloan, Bruce R Schackman, et al.
HIV Clinical Trials|January 18, 2011
Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patientsNatasha N Pettit, Daryl D DePestel, Preeti N Malani, et al.
HIV Clinical Trials|January 18, 2011
Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapyJanet Raboud, Sandra Blitz, Sharon Walmsley, et al.
HIV Clinical Trials|October 25, 2007
Efficacy, safety, and tolerability of long-term combination antiretroviral therapy in asymptomatic treatment-naïve adults with early HIV infectionDeborah K McMahon, Mark J Dinubile, Anne R Meibohm, et al.
HIV Clinical Trials|October 25, 2007
Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patientsFranco Maggiolo, Monica Airoldi, Hendrik Daniël Kleinloog, et al.
HIV Clinical Trials|December 20, 2011
Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adultsCurtis Cooper, Anona Thorne,
HIV Clinical Trials|April 19, 2012
Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patientsJuan Macías, Karin Neukam, Josep Mallolas, et al.
HIV Clinical Trials|April 19, 2012
Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access programAdriano Lazzarin, Soe Than, Srinivas R Valluri, et al.
HIV Clinical Trials|April 19, 2012
Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapyJ Raboud, A Anema, D Su, et al.
Pageof 68